Literature DB >> 164634

Reovirus antibody patterns in dogs: a trial for the application of principal component analysis to seroepidemiology.

T Murakami, H Kato.   

Abstract

In 100 dogs in Morioka and its vicinity serologically surveyed for reovirus infection, there were significant correlations between hemagglutination-inhibiting and neutralizing antibody titers of the same virus types. In order to establish a proper index for the evaluation of infection, principal component analysis was applied to the analysis of data, including standard immune sera. Of nine samples of matrix examined, correlation matrix of 6 variables was suggested to afford the most proper result. Essential information from the original data was accounted for by factor loadings of the first 3 components. The 6 attributes of serum antibody were classified into three groups. In a scatter diagram serum samples were classified also into three major groups corresponding to the three reovirus types, and the serotypic pattern of infection was clearly visualized.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 164634

Source DB:  PubMed          Journal:  Natl Inst Anim Health Q (Tokyo)        ISSN: 0027-951X


  3 in total

1.  Oncolytic reovirus in canine mast cell tumor.

Authors:  Chung Chew Hwang; Saori Umeki; Masahito Kubo; Toshiharu Hayashi; Hiroshi Shimoda; Masami Mochizuki; Ken Maeda; Kenji Baba; Hiroko Hiraoka; Matt Coffey; Masaru Okuda; Takuya Mizuno
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

2.  Detection and Characterization of a Novel Reassortant Mammalian Orthoreovirus in Bats in Europe.

Authors:  Davide Lelli; Ana Moreno; Andrej Steyer; Tina Nagliˇc; Chiara Chiapponi; Alice Prosperi; Francesca Faccin; Enrica Sozzi; Antonio Lavazza
Journal:  Viruses       Date:  2015-11-11       Impact factor: 5.048

3.  Seroepidemiology of reovirus in healthy dogs in six prefectures in Japan.

Authors:  Chung Chew Hwang; Masami Mochizuki; Ken Maeda; Masaru Okuda; Takuya Mizuno
Journal:  J Vet Med Sci       Date:  2013-11-27       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.